Literature DB >> 17525686

The role of adherence to antiretroviral therapy in the management of HIV infection.

Brian Conway1.   

Abstract

Despite multiple studies demonstrating the relation between the success of highly active antiretroviral therapy (HAART) and adherence, inadequate adherence continues to be one of the most frequent reasons for poor treatment outcomes and/or lack of sustained treatment benefits. Interventions targeting patient-related social and psychologic barriers to adherence and issues related to mental health and substance abuse and access to health care may ameliorate their negative impact on adherence. Specific drug-related factors that influence adherence such as pill burden, dosing frequency, food requirements, and acute tolerability and safety concerns, however, are further issues that must be considered to optimize adherence. Fortunately, the availability of once-daily and coformulated agents with simple dosing requirements may help to improve adherence, and thereby make the difference between success and failure of HAART for some patients. A better understanding of adherence and its determinants and how to define specific goals in a given clinical setting are keys for clinicians to become more effective partners with patients in the achievement and maintenance of long-term virologic suppression and, more importantly, long-term health.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17525686     DOI: 10.1097/QAI.0b013e3180600766

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  37 in total

1.  Two-way text messaging for health behavior change among human immunodeficiency virus-positive individuals.

Authors:  Lynne T Harris; Keren Lehavot; David Huh; Samantha Yard; Michele P Andrasik; Peter J Dunbar; Jane M Simoni
Journal:  Telemed J E Health       Date:  2010-11-18       Impact factor: 3.536

2.  Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage.

Authors:  Rafael F Bressani; Ari S Nowacek; Sangya Singh; Shantanu Balkundi; Barrett Rabinow; Joellyn McMillan; Howard E Gendelman; Georgette D Kanmogne
Journal:  Nanotoxicology       Date:  2010-12-22       Impact factor: 5.913

Review 3.  Cell Phone-Based and Adherence Device Technologies for HIV Care and Treatment in Resource-Limited Settings: Recent Advances.

Authors:  Jeffrey I Campbell; Jessica E Haberer
Journal:  Curr HIV/AIDS Rep       Date:  2015-12       Impact factor: 5.071

4.  Design of a randomized trial to evaluate the influence of mobile phone reminders on adherence to first line antiretroviral treatment in South India--the HIVIND study protocol.

Authors:  Ayesha De Costa; Anita Shet; Nagalingeswaran Kumarasamy; Per Ashorn; Bo Eriksson; Lennart Bogg; Vinod K Diwan
Journal:  BMC Med Res Methodol       Date:  2010-03-26       Impact factor: 4.615

5.  Discontinuation of antiretroviral therapy among adults receiving HIV care in the United States.

Authors:  Alison J Hughes; Christine L Mattson; Susan Scheer; Linda Beer; Jacek Skarbinski
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

6.  Simultaneous determination of antiretroviral drugs in human hair with liquid chromatography-electrospray ionization-tandem mass spectrometry.

Authors:  Yan Wu; Jin Yang; Cailing Duan; Liuxi Chu; Shenghuo Chen; Shan Qiao; Xiaoming Li; Huihua Deng
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-03-11       Impact factor: 3.205

7.  A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Authors:  Matt S Anderson; Sauzanne Khalilieh; Ka Lai Yee; Rachael Liu; Li Fan; Matthew L Rizk; Vedangi Shah; Azra Hussaini; Ivy Song; Lisa L Ross; Joan R Butterton
Journal:  Clin Pharmacokinet       Date:  2017-06       Impact factor: 6.447

8.  Adherence to antiretroviral medication in older adults living with HIV/AIDS: a comparison of alternative models.

Authors:  Christopher J Johnson; Timothy G Heckman; Nathan B Hansen; Arlene Kochman; Kathleen J Sikkema
Journal:  AIDS Care       Date:  2009-05

9.  Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis.

Authors:  Eran Bendavid; Robin Wood; David A Katzenstein; Ahmed M Bayoumi; Douglas K Owens
Journal:  J Acquir Immune Defic Syndr       Date:  2009-09-01       Impact factor: 3.731

10.  Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.

Authors:  Graeme Moyle; Marta Boffito; Carl Fletcher; Chris Higgs; Phillip E Hay; Ivy H Song; Yu Lou; Geoffrey J Yuen; Sherene S Min; Elena M Guerini
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.